- Boehringer Ingelheim has entered a licence and collaboration agreement with Simcere Pharmaceutical Group to develop SIM0709, a pre-clinical bispecific antibody for inflammatory bowel disease.
- Under the agreement, Simcere is eligible to receive upfront and success-based milestone payments totalling up to €1,058 million, plus royalties on net sales outside Greater China.
Boehringer Ingelheim and Simcere Pharmaceutical Group have signed a licence and collaboration agreement to develop SIM0709, a pre-clinical TL1A/IL-23p19 bispecific antibody, for the treatment of inflammatory bowel disease (IBD). The partnership aims to advance the candidate through global development.
SIM0709 is a long-acting, humanised bispecific antibody developed by Simcere using its proprietary multi-specific antibody platform. The molecule simultaneously targets TL1A and IL-23, blocking two pathways involved in the onset and progression of IBD. According to the companies, the candidate demonstrated synergistic efficacy in in vitro primary cell studies and in vivo animal studies.
“In IBD, too many patients continue to progress and experience severe complications despite currently available anti-inflammatory therapies. We are excited to join forces with Simcere to accelerate the development of this therapeutic as a potential life-changing option for patients living with IBD.”
Carine Boustany, US Innovation Unit Site Head and Global Head of Immunology and Respiratory Diseases at Boehringer Ingelheim
Under the terms of the agreement, Boehringer Ingelheim receives global rights to SIM0709, excluding Greater China. Simcere is eligible to receive an upfront payment and development, regulatory and sales milestones of up to €1,058 million, as well as royalties on net sales outside the Greater China territory.
